A Phase 2, Randomized, Double-Blind, Placebo Controlled Study Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Subjects With Primary Biliary Cholangitis Without Cirrhosis
Phase of Trial: Phase II
Latest Information Update: 28 Jul 2017
At a glance
- Drugs GS 9674 (Primary)
- Indications Primary biliary cirrhosis
- Focus Adverse reactions
- Sponsors Gilead Sciences
- 11 Apr 2017 Planned End Date changed from 1 Jul 2019 to 1 Feb 2020.
- 11 Apr 2017 Planned primary completion date changed from 1 Aug 2017 to 1 Oct 2017.
- 14 Nov 2016 Status changed from not yet recruiting to recruiting, as per the Gilead Sciences media release.